Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974545 | 0.85 | PKM (0.46) | ITGB1ITGA4KEAP1PKMHTR6 | |
| SCHEMBL24974368 | 0.75 | PKM (0.47) | ITGB1ITGA4KEAP1PKMHTR6 | |
| SCHEMBL24974776 | 0.74 | PKM (0.49) | KEAP1PKMHTR6WDR5HSPA8 | |
| SCHEMBL24974540 | 0.71 | PKM (0.47) | PKMHTR6HSPA8PTPN2PTPN1 | |
| SCHEMBL24974633 | 0.69 | PKM (0.47) | KEAP1PKMHTR6 | |
| SCHEMBL24974743 | 0.67 | OPRM1 (0.48) | KEAP1PKMCA12CA1CA2 | |
| SCHEMBL23625180 | 0.63 | CA12 (0.60) | KEAP1PKMSLC6A3CA12CA1 | |
| SCHEMBL26073697 | 0.63 | CA12 (0.64) | ITGB1ITGA4KEAP1PKMCA12 | |
| SCHEMBL20280336 | 0.62 | TDP1 (0.65) | PKMCA12CA1CA2CA9 | |
| SCHEMBL19960776 | 0.62 | TDP1 (0.65) | PKMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ITGB1 98/4885ITGA4 85/4885KEAP1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.